A challenge that anyone working to bring new technology, therapies, or approaches from proof of concept to clinic implementation is funding. I have been tracking the concept of crowd funding for a number of years, but have not seen many platforms that offer the opportunity to raise funding to a degree that will really make a difference.
So, I was enthusiastic when I met Pilar Puig Sàrries and learned about the work she is doing at Capital Cell, a crowdfunding platform specializing in the life sciences. She is the head the BioExpert Network and life sciences analytics at Capital Cell and passionate about her work to help startups in the life sciences bridge the translational gap.
How did you start doing what you are doing now?
During my PhD in molecular biology I felt uncertain about becoming a Spanish researcher because in Spain every 1-3 years you need to apply for further support for your research which means no stability.
So, during my PhD I began my first startup. It was an online/offline game for couples. I was able to sell 1.000 games after closing a successful crowdfunding campaign, which in my mind was pretty successful. But I also had to write my thesis and I also had a big interest in travel.
After my PhD I took a 9 month trip to South America and those 9 months were the happiest time of my life. When I came back, I knew that I didn’t want to keep doing research, so it seemed ideal to do something related to science, but also related to entrepreneurship. I was fortunate to find an opportunity at Capital Cell as a life science analyst.
What do you do at Capital Cell?
Capital cell is a start-up which means anyone working there has many roles. My job title is life science analyst, but I also do business development for clients such as helping them with their business models and building their pitch. We also help them look for investors as well. I also produce content for the website. Last year with the CEO of Capital Cell we created the BioExpert Network which is a network of experts who help us evaluate and select companies to be included in our crowdfunding platform.
Can you explain a bit about the philosophy behind Capital Cell and how it works?
Capital Cell is the first equity crowdfunding specialized in life sciences in Europe. And since last September, we are also operating in the UK.
We help companies in the life science sector get funded. Most of them are in the ‘valley of death’, which is also called the translational gap. They may have proof of concept, but need capital to continue to get scientific validation. We are now working with some companies that are further along, but still need to have some more funding before approaching VCs.
Image Credit: Shutterstock.com
News This Week
Researchers from Hong Kong Baptist University (HKBU), in collaboration with Cornell University, have developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound [...]
By early 2020, concern was mounting about a new, deadly coronavirus first detected in Wuhan, China. The World Health Organization had declared the coronavirus outbreak a global health emergency just days before. There had been [...]
As a COVID-19 and medical device researcher, I understand the importance of face masks to prevent the spread of the coronavirus. So I am intrigued that some mask manufacturers have begun adding graphene coatings [...]
Swansea University scientists have uncovered potentially dangerous chemical pollutants that are released from disposable face masks when submerged in water. The research reveals high levels of pollutants, including lead, antimony, and copper, within the [...]
Bowel cancer survival rates could be improved if chemotherapy drugs were delivered via tiny nanoparticles to the diseased organs rather than oral treatment. That's the finding from Indian and Australian scientists who have undertaken [...]
Pfizer CEO Albert Bourla says his company’s experimental COVID-19 treatment, a pill that can be taken at the first sign of the illness, could be available before the end of the year. Speaking on CNBC, Bourla said clinical [...]
At the University of Chicago, scientists have developed an absolutely innovative, promising treatment for COVID-19 in the form of nanoparticles with the ability to trap SARS-CoV-2 viruses inside the body and use the body’s [...]